Pharsight to Host Brussels Seminar on Challenges in the Adoption of Modeling and Simulation to Support Model-Based Drug Development

Mountain View, California (ots/PRNewswire) -

- Case Studies of Modeling Projects Will be Presented, Together
with a Discussion of Technical, Organizational, and Process Changes
Needed to Address the Critical Path Initiative

Pharsight Corporation (OTC Bulletin Board: PHST), a leading
provider of software and strategic services for optimizing clinical
drug development, announced today that Dan Weiner, Ph.D., Senior Vice
President, Software, and Dr. Rene Bruno, Managing Director of
Strategic Consulting Services, Europe, will lead an interactive
workshop on challenges in the implementation of modeling and
simulation as outlined in FDA's Critical Path on September 6, 2006 at
9 AM local (Brussels) time in the Crowne Plaza Hotel at Brussels
Airport. More information is available at
http://phx.corporate-ir.net/phoenix.zhtml?c=121504&p=irol-calendar .

"The FDA Critical Path Initiative is a challenge to build
model-based drug development into the pharmaceutical development
process. The changes needed include technical, organizational,
process, and others both specific to modeling and simulation and
general to any change initiative," said Shawn O'Connor, Pharsight
president, CEO and chairman. "This workshop will identify what
leading companies are doing to implement these changes and realize
the promise of the Critical Path through modeling and simulation."

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and
services that enable pharmaceutical and biotechnology companies to
achieve significant and enduring improvements in the development and
use of therapeutic products. The company's goal is to help customers
reduce the time, cost and risk of drug development, as well as
optimize the post-approval marketing and use of pharmaceutical
products.

Pharsight's approach enhances the fundamental element of drug
development success: strong decision-making. By adopting the
Pharsight approach, customers acquire a new decision-making process
with the potential to systematically improve every level and phase of
their business and scientific processes. Pharsight Corporation is
headquartered in Mountain View, California. Information about
Pharsight is available at http://www.pharsight.com .

Registered Trademarks and Trademarks
Pharsight(R) is a registered trademark of Pharsight Corporation.

Web site: http://www.pharsight.com

ots Originaltext: Pharsight Corporation
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Investors, Douglas Sherk, or Jennifer Beugelmans, both of EVC Group,
+1-415-896-6820; or Media, Steve DiMattia of EVC Group,
+1-646-277-8706